Spots Global Cancer Trial Database for CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
Official Title: Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma
Study ID: NCT03672253
Interventions
Study Description
Brief Summary: This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Contact Details
Name: Wan-Hong Zhao, MD, PhD
Affiliation: Second Affiliated Hospital of Xi'an Jiaotong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
